Skip to main content
SpringerLink
Log in

Spezielle mesenchymale Tumoren der Kopf-Hals-Region: Neues aus der WHO 2022

Special mesenchymal neoplasms of the head and neck: Update from the 2022 WHO

  • Schwerpunkt: Kopf-Hals-Pathologie – neue WHO-Klassifikation
  • Published:
Die Pathologie Aims and scope Submit manuscript

Zusammenfassung

Ein neues Merkmal der aktuellen WHO-Klassifikation der Kopf-Hals-Tumoren (ähnlich der WHO-Klassifikation sonstiger Organe) ist die separate Auflistung mesenchymaler Tumoren in einer gesonderten Sektion am Ende des Buches. Dabei wurden Weichteiltumoren mit Prädilektion für die Kopf-Hals-Region aus den bisherigen Einzellokalisationen/Organen entfernt und in diesem gesonderten mesenchymalen Kapitel erfasst. Hier sind sowohl ältere wie der phosphaturische mesenchymale Tumor als auch neuere wie GLI1-alterierte Tumoren aufgeführt. Lediglich Tumoren mit nahezu ausschließlichem Auftreten in bestimmten Organen (wie das nasopharyngeale Angiofibrom, das sinunasale Glomangioperizytom und das biphänotypische sinunasale Sarkom) sind in den entsprechenden Lokalisationen/Organen erhalten geblieben. Die Erfassung bestimmter neuer Entitäten in der aktuellen Klassifikation sollte das Erkennen dieser noch wenig bekannten Tumoren positiv beeinflussen. Im Folgenden werden die wichtigsten Aspekte dieser Entitäten dargestellt und deren Differenzialdiagnosen besprochen.

Abstract

Similar to the approach adopted in the classification of tumors in other organs, a new feature of the current Word Health Organization (WHO) classification of the head and neck tumors is the exclusion of soft tissue tumors from single organs and their inclusion in a separate chapter devoted to them. This applies to tumors that are principally ubiquitous but show a predilection for the head and neck sites. The only exception to this rule represents those entities that are almost restricted to a specific head and neck site/organ (such as nasopharyngeal angiofibroma, sinonasal glomangiopericytoma, and biphenotypic sinonasal sarcoma), which remain in their respective organ chapters. Included among soft tissue tumors are some old but still underrecognized entities, such as phosphaturic mesenchymal tumors, and newly defined entities, such as GLI1-altered tumors. The aim of including these entities is to enhance recognition of these uncommon but likely under-recognized entities to better characterize them in the future. This review summarizes the main features of these rare entities and discusses their differential diagnoses.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3
Abb. 4
Abb. 5

Literatur

  1. WHO Classification of Tumours Editorial Board (2022). Head and neck tumours. Lyon (France): International Agency for Research on Cancer. (WHO classification of tumours series, 5th ed.; vol. 9). https://publications.iarc.fr/

    Google Scholar 

  2. Leiner J, Le Loarer F (2020) The current landscape of rhabdomyosarcomas: an update. Virchows Arch 476:97–108

    Article  PubMed  Google Scholar 

  3. Thompson LDR, Bishop JA (2022) Update from the 5th edition of the World Health Organization classification of head and neck tumors: nasal cavity, paranasal sinuses and skull base. Head Neck Pathol 16:1–18

    Article  PubMed  PubMed Central  Google Scholar 

  4. Thompson LDR, Jo VY, Agaimy A et al (2018) Sinonasal tract alveolar rhabdomyosarcoma in adults: a clinicopathologic and immunophenotypic study of fifty-two cases with emphasis on epithelial immunoreactivity. Head Neck Pathol 12:181–192

    Article  PubMed  Google Scholar 

  5. Meyer A, Klubíčková N, Mosaieby E et al (2023) Biphenotypic sinonasal sarcoma with PAX3::MAML3 fusion transforming into high-grade rhabdomyosarcoma: report of an emerging rare phenomenon. Virchows Arch 482:777–782

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Owosho AA, Chen S, Kashikar S et al (2016) Clinical and molecular heterogeneity of head and neck spindle cell and sclerosing rhabdomyosarcoma. Oral Oncol 58:e6–e11

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Arnold MA, Barr FG (2017) Molecular diagnostics in the management of rhabdomyosarcoma. Expert Rev Mol Diagn 17:189–194

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Butel T, Karanian M, Pierron G et al (2020) Integrative clinical and biopathology analyses to understand the clinical heterogeneity of infantile rhabdomyosarcoma: A report from the French MMT committee. Cancer Med 9:2698–2709

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Bisogno G, Minard-Colin V, Arush MB et al (2022) Congenital rhabdomyosarcoma: a report from the European paediatric soft tissue sarcoma study group. Pediatr Blood Cancer 69:e29376

    Article  CAS  PubMed  Google Scholar 

  10. Mosquera JM, Sboner A, Zhang L et al (2013) Recurrent NCOA2 gene rearrangements in congenital/infantile spindle cell rhabdomyosarcoma. Genes Chromosomes Cancer 52:538–550

    Article  CAS  PubMed  Google Scholar 

  11. Alaggio R, Zhang L, Sung YS et al (2016) A molecular study of pediatric spindle and sclerosing rhabdomyosarcoma: identification of novel and recurrent VGLL2-related fusions in infantile cases. Am J Surg Pathol 40:224–235

    Article  PubMed  PubMed Central  Google Scholar 

  12. Le Loarer F, Cleven AHG, Bouvier C et al (2020) A subset of epithelioid and spindle cell rhabdomyosarcomas is associated with TFCP2 fusions and common ALK upregulation. Mod Pathol 33:404–419

    Article  PubMed  Google Scholar 

  13. Whittle S, Venkatramani R et al (2022) Congenital spindle cell rhabdomyosarcoma: An international cooperative analysis. Eur J Cancer 168:56–64

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Agaimy A, Dermawan JK, Leong I et al (2022) Recurrent VGLL3 fusions define a distinctive subset of spindle cell rhabdomyosarcoma with an indolent clinical course and striking predilection for the head and neck. Genes Chromosomes Cancer 61(12):701–709

    Article  CAS  PubMed  Google Scholar 

  15. Agaram NP, LaQuaglia MP, Alaggio R et al (2019) MYOD1-mutant spindle cell and sclerosing rhabdomyosarcoma: an aggressive subtype irrespective of age. A reappraisal for molecular classification and risk stratification. Mod Pathol 32:27–36

    Article  CAS  PubMed  Google Scholar 

  16. Rooper LM, Uddin N, Gagan J et al (2020) Recurrent loss of SMARCA4 in sinonasal teratocarcinosarcoma. Am J Surg Pathol 44:1331–1339

    Article  PubMed  Google Scholar 

  17. Slootweg PJ, Lubsen H (1991) Rhabdomyoblasts in olfactory neuroblastoma. Histopathology 19:182–184

    Article  CAS  PubMed  Google Scholar 

  18. Huang S‑C, Ghossein RA, Bishop JA et al (2016) Novel PAX3-NCOA1 fusions in biphenotypic sinonasal sarcoma with focal rhabdomyoblastic differentiation. Am J Surg Pathol 40(29):51–59

    Article  PubMed  PubMed Central  Google Scholar 

  19. Agaram NP, Zhang L, Sung YS et al (2019) Expanding the spectrum of Intraosseous rhabdomyosarcoma: correlation between 2 distinct gene fusions and phenotype. Am J Surg Pathol 43(5):695–702

    Article  PubMed  PubMed Central  Google Scholar 

  20. Xu B, Suurmeijer AJH, Agaram NP, Zhang L, Antonescu CR (2021) Head and neck rhabdomyosarcoma with TFCP2 fusions and ALK overexpression: a clinicopathological and molecular analysis of 11 cases. Histopathology 79:347–357

    Article  PubMed  PubMed Central  Google Scholar 

  21. Agaram NP, Zhang L, Cotzia P, Antonescu CR (2018) Expanding the spectrum of genetic alterations in pseudomyogenic hemangioendothelioma with recurrent novel ACTB-FOSB gene fusions. Am J Surg Pathol 42:1653–1661

    Article  PubMed  PubMed Central  Google Scholar 

  22. Folpe AL, Fanburg-Smith JC, Billings SD et al (2004) Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol 28:1–30

    Article  PubMed  Google Scholar 

  23. Agaimy A, Michal M, Chiosea S et al (2017) Analysis of 22 Cases Expanding their Morphologic and Immunophenotypic Spectrum. Am J Surg Pathol 41:1371–1380

    Article  PubMed  Google Scholar 

  24. Hulme KR, Mahar A, Campbell RG et al (2022) Phosphaturic mesenchymal tumors in the head and neck demonstrate a broad clinical and morphologic spectrum. Head Neck Pathol 16:902–912

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Carter JM, Caron BL, Dogan A, Folpe AL (2015) A novel chromogenic in situ hybridization assay for FGF23 mRNA in phosphaturic mesenchymal tumors. Am J Surg Pathol 39:75–83

    Article  PubMed  Google Scholar 

  26. Sent-Doux KN, Mackinnon C, Lee JC, Folpe AL, Habeeb O (2018) Phosphaturic mesenchymal tumor without osteomalacia: additional confirmation of the “nonphosphaturic” variant, with emphasis on the roles of FGF23 chromogenic in situ hybridization and FN1-FGFR1 fluorescence in situ hybridization. Hum Pathol 80:94–98

    Article  CAS  PubMed  Google Scholar 

  27. Lee JC, Su SY, Changou CA et al (2016) Characterization of FN1-FGFR1 and novel FN1-FGF1 fusion genes in a large series of phosphaturic mesenchymal tumors. Mod Pathol 29:1335–1346

    Article  CAS  PubMed  Google Scholar 

  28. Liu YJ, Wang W, Yeh J, Wu Y et al (2021) Calcified chondroid mesenchymal neoplasms with FN1-receptor tyrosine kinase gene fusions including FGFR2, FGFR1, MERTK, NTRK1, and TEK: a molecular and clinicopathologic analysis. Mod Pathol 34:1373–1383

    Article  CAS  PubMed  Google Scholar 

  29. Antonescu CR, Agaram NP, Sung YS et al (2018) A distinct malignant epithelioid neoplasm with GLI1 gene rearrangements, frequent S100 protein expression, and metastatic potential: expanding the spectrum of pathologic entities with ACTB/MALAT1/PTCH1-GLI1 fusions. Am J Surg Pathol 42:553–560

    Article  PubMed  PubMed Central  Google Scholar 

  30. Agaram NP, Zhang L, Sung YS et al (2019) GLI1-amplifications expand the spectrum of soft tissue neoplasms defined by GLI1 gene fusions. Mod Pathol 32:1617–1626

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Xu B, Chang K, Folpe AL et al (2020) Head and neck mesenchymal neoplasms with GLI1 gene alterations: a pathologic entity with distinct histologic features and potential for distant metastasis. Am J Surg Pathol 44:729–737

    Article  PubMed  PubMed Central  Google Scholar 

  32. Liu J, Mao R, Lao IW, Yu L, Bai Q, Zhou X, Wang J (2022) GLI1-altered mesenchymal tumor: a clinicopathological and molecular analysis of ten additional cases of an emerging entity. Virchows Arch 480:1087–1099

    Article  CAS  PubMed  Google Scholar 

  33. Papke DJ Jr, Dickson BC, Sholl L, Fletcher CDM (2022) Pseudoendocrine sarcoma: clinicopathologic analysis of 23 cases of a distinctive soft tissue neoplasm with metastatic potential, recurrent CTNNB1 mutations, and a predilection for truncal locations. Am J Surg Pathol 46:33–43

    Article  PubMed  Google Scholar 

  34. Agaimy A, Ihrler S, Märkl B, Lell M, Zenk J, Hartmann A, Michal M, Skalova A (2013) Lipomatous salivary gland tumors: a series of 31 cases spanning their morphologic spectrum with emphasis on sialolipoma and oncocytic lipoadenoma. Am J Surg Pathol 37:128–137

    Article  PubMed  Google Scholar 

  35. Dickson BC, Antonescu CR, Argyris PP et al (2018) Ectomesenchymal chondromyxoid tumor: a neoplasm characterized by recurrent RREB1-MKL2 fusions. Am J Surg Pathol 42:1297–1305

    Article  PubMed  PubMed Central  Google Scholar 

  36. Mechtersheimer G, Andrulis M, Delank KW et al (2021) RREB1-MKL2 fusion in a spindle cell sinonasal sarcoma: biphenotypic sinonasal sarcoma or ectomesenchymal chondromyxoid tumor in an unusual site? Genes Chromosomes. Cancer 60:565–570

    CAS  Google Scholar 

  37. Agaimy A, Din NU, Dermawan JK et al (2023) RREB1::MRTFB fusion-positive extra-glossal mesenchymal neoplasms: A series of five cases expanding their anatomic distribution and highlighting significant morphological and phenotypic diversity. Genes Chromosomes Cancer 62:5–16

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pathologisches Institut, Universitätsklinikum Erlangen, Krankenhausstr. 8–10, 91054, Erlangen, Deutschland

    Abbas Agaimy

  2. Abteilung für translationale Forschung und neue Technologien in Medizin und Chirurgie, Universität Pisa, Pisa, Italien

    Alessandro Franchi

Authors
  1. Abbas Agaimy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alessandro Franchi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Abbas Agaimy.

Ethics declarations

Interessenkonflikt

A. Agaimy und A. Franchi geben an, dass kein Interessenkonflikt besteht.

Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Additional information

Schwerpunktherausgeber

A. Agaimy, Erlangen

S. Ihrler, München

figure qr

QR-Code scannen & Beitrag online lesen

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Agaimy, A., Franchi, A. Spezielle mesenchymale Tumoren der Kopf-Hals-Region: Neues aus der WHO 2022. Pathologie 44, 250–258 (2023). https://doi.org/10.1007/s00292-023-01203-7

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00292-023-01203-7

Schlüsselwörter

Keywords

Search

Navigation